Nanomedicines for Therapy of Bladder Cancer
10.22465/kjuo.2022.20.4.235
- Author:
Cheeun SONG
1
;
Seung Ju JANG
;
Woo Hyeok JEON
;
Sejung MAENG
;
Jong Hyun TAE
;
In Ho CHANG
Author Information
1. Department of Medicine, Chung-Ang University College of Medicine, Seoul, Korea
- Publication Type:Review Article
- From:Korean Journal of Urological Oncology
2022;20(4):235-247
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Bladder cancer is one of most common malignant urinary tract tumor types, and transurethral resection of nonmuscle invasive bladder cancer followed by intravesical instillation of immunochemotherapy is the standard treatment approach to minimize recurrence and delay progression of bladder cancer. In general, conventional intravesical immunochemotherapy lacks selectivity for tumor tissues and the effect of drug is reduced with the excretion of urine leading to frequent administration and bladder irritation symptoms. Recently, nanomedicines which adhere to the bladder tumors for a long time, and continuously and efficiently release drug to bladder cancers may overcome all the above problems. Moreover, the advances in nanomedicine based targeted therapy have led to significant improvements in drug efficacy and precision of targeted drug delivery. This review shows the available nano-systems of targeted drug delivery to bladder cancer tissues.
